Non-Clear Cell RCC Clinical Trials

Have you been diagnosed with non-clear cell RCC? Clinical trials are an excellent way for patients to access new treatments for rare subtypes. This chart lists all active and enrolling clinical trials for non-clear cell RCC.

Click on the NCI Trial ID to learn more about each non-clear cell RCC trial including eligibility criteria and information about enrollment. Listing a study is not an endorsement of any clinical trial.

To learn more about the different subtypes of RCC, click here.

If you have information about non-clear cell clinical trials or would like to suggest an addition or change, contact

NCI Trial IDHistologyTreatmentPhaseLocations
NCT02724878Non-clear Cell RCC[Atezolizumab + bevacizumab] (immunotherapy + targeted therapy)IIMI, CA, MA
NCT03075423 SUNIFORECASTNon-clear Cell RCCIpilimumab + nivolumab vs. sunitinib IIGermany
NCT03685448Non-clear Cell RCCCabozantinib for patients post-immunotherapy or who are ineligible for immunotherapyIIAustralia
NCT03635892Non-Clear Cell RCC[Nivolumab + cabozantinib] (immunotherapy + targeted therapy)IINJ, NY
NCT02626130Non-Clear Cell & Clear Cell RCCTremelimumab with or without cryoablation (immunotherapy in patients undergoing surgery)IHouston, TX
NCT03117309Non-Clear Cell & Clear Cell RCCNivolumab and [nivolumab + ipilimumab] (combination immunotherapy)IIDC, IL, MA, NJ, NY, OH, PA, TX
NCT01638533Non-Clear Cell & Clear Cell RCC patients with moderate to severe liver dysfunctionRomidepsin (targeted therapy HDAC inhibitor)ICA, GA, IL, MD, MI, MN, OH, PA, WI, Canada
NCT03149822Non-Clear Cell & Clear Cell RCC[Pembrolizumab + cabozantinib] (immunotherapy and targeted therapy)I/IICO
NCT03055013 PROSPER RCCNon-Clear Cell & Clear Cell RCC (Neoadjuvant Therapy - Non-metastatic)Nivolumab prior to and after nephrectomy (neoadjuvant immunotherapy)III38 states in U.S.
NCT02721732Renal Medullary Carcinoma, Non-Clear Cell and Clear CellPembrolizumab (immunotherapy)IIHouston, TX
NCT02495103Non-Clear Cell & Clear Cell RCC (Including HLRCC)[Vandetanib + Metformin] (targeted therapy + blood glucose regulator)I/IIBethesda, MD (NIH)
NCT02019693Papillary RCCCapmatinib (INC280) (targeted therapy MET inhibitor)IIBethesda, MD (NIH)
NCT02761057Papillary RCCCabozantinib or crizotinib or volitinib vs. sunitinib (targeted therapy MET inhibitors vs. VEGF inhibitor)II37 states in U.S. and Canada
NCT03319628Papillary RCCXMT-1536 (immunoconjugate therapy)IMA, OK, PA, SC, TN, TX
NCT03175224Papillary or Clear Cell RCC (MET gene driven)CBT-101 (targeted therapy c-MET inhibitor)IAZ, CA, FL, MN
NCT03866382Papillary RCC, Chromophobe RCC, Sarcomatoid RCC and Renal Medullary Carcinoma
[Nivolumab + ipilimumab + cabozantinib] (combination immunotherapy and targeted therapy)IIID, MT, NE, OR, WY
NCT02363751 BEVABELCollecting Duct RCC[Gemcitabine + platinum + bevacizumab] (chemotherapy + targeted therapy)IIFrance
NCT03595124Translocation XP11.2[Nivolumab + axitinib] or axitinib or nivolumab (immunotherapy and/or targeted therapy)II25 states in U.S.
NCT03165721HLRCC-Associated RCCGuadecitabine (SGI-110) (DNA methyltransferase inhibitor)IIBethesda, MD (NIH)
NCT03274258Renal Medullary Carcinoma (RMC)[Nivolumab + ipilumumab] (combination immunotherapy)IIHouston, TX
NCT02496208Renal Medullary Carcinoma, Sarcomatoid RCC, Clear Cell RCC, and Other Rare Kidney Cancer Histology[Nivolumab + cabozantinib] or [nivolumab + ipilimumab + cabozantinib] (immunotherapy + targeted therapy)ICA, MD, NJ, OH
NCT02601950Renal Medullary Carcinoma and Malignant Rhabdoid Tumor with INI1 (SMARCB1) loss (Ages 16+)Tazemetostat (targeted therapy EZH2 inhibitor)II12 states in U.S., Australia, Belgium, Canada, France, Germany, Italy, Taiwan, UK
NCT03587662Renal Medullary Carcinoma and other tumors with loss of SMARCB1; including adult-onset rhabdoid tumorsIxazomib, Gemcitabine and Doxorubicin (chemotherapy + targeted therapy)IIHouston, TX
NCT03541902Variant histology RCC (vhRCC) Including Papillary RCC, Chromophobe RCC, Xp11.2 Translocation, Undifferentiated and Unclassified RCCCabozantinib or sunitinib (targeted therapy)IIHouston, TX
NCT02465060 MATCHGenetic Based Kidney Cancer (Therapy directed by genetic testing)22 different targeted therapy agents for EGFR, HER2, MET, ALK, ROS1, BRAF, PIK3CA, mTOR, TSC1, TSC2, PTEN, NF1, GNAQ, GNA11, SMO, PTCH1, NF2, cKIT, FGFR, DDR2 S768R, I638F, L239R, AKT, NRAS, CCND, CDK4, CDK6, MLH, NTRK, BRCA gene mutationsII50 states in the U.S.
NCT04068831FH/SDH positive tumorsAvelumab (PD-L1 inhibitor) + Talazoparib (PARP inhibitor)IINew York, NY
NCT03097328All types of RCCTAK-228IICA, CO, IL, MA, MI, MN

Lost Password


Subscribe for updates!